Hematologic Malignancy
Plasma Cell Leukemia
CI-CAN-00001421PCLExplore in graph →
Hematologic23 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001421PCLExplore in graph →
Clinical trials
53 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials